In this prospective randomized phase-II study, we directly compared the mobilization potential of cytokine stimulation with G-CSF alone versus combined chemotherapy with vinorelbine and G-CSF (or in case of relevant neuropathy with gemcitabine and G-CSF) applying a non-inferiority design. The gene discussed is CSF3; the disease is neuropathy.